Acute Lymphoid Leukemia Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute lymphoid leukemia disease. 15 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
15
Active US patents
49/100
Avg vulnerability
$1.0B
Annual revenue covered

Originators in Acute Lymphoid Leukemia Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Baxter 15 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute lymphoid leukemia disease. Each bar = one year. Y-axis scaled to peak year (9 patents).

9
35
6
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cytoxan (Lyophilized)
cyclophosphamide
 Baxter 15 49 $1.0B 2035-06-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
9662342 Cytoxan (Lyophilized) formulation 50 2035-06-26
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
10993952 Cytoxan (Lyophilized) formulation 50 2036-02-15
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13

Related